New evidence published supporting use of decisiondx®-scc test in guiding and improving treatment pathway decisions in nccn high-risk cutaneous squamous cell carcinoma

New validation study shows decisiondx-scc significantly outperforms current staging systems in predicting risk of local recurrence and metastasis for nccn high-risk patients clinician survey confirms test results align with treatment decision-making thresholds for adjuvant radiation therapy and surveillance imaging friendswood, texas, aug. 25, 2025 (globe newswire) -- castle biosciences, inc. (nasdaq: cstl), a company improving health through innovative tests that guide patient care, today announced the publication of two new studies related to its decisiondx-scc test, adding to its validated uses for patients with high-risk cutaneous squamous cell carcinoma (scc).1,2 decisiondx-scc is a gene expression profile test (40-gep) designed to use a patient's tumor biology to predict individual risk of metastasis as well as response to adjuvant radiation therapy (art). the first study represents an expanded clinical use milestone, demonstrating that decisiondx-scc predicts local recurrence in patients classified as high-risk by national comprehensive cancer network (nccn) guidelines who have undergone mohs resection, thereby adding a third use to the test's existing capabilities.
CSTL Ratings Summary
CSTL Quant Ranking